As elevated Trx1 levels impacted binding of Tregalizumab with CD4 in vitro, we determined Trx1 concentrations in RA patients retrospectively to find a correlation between Trx1 levels and efficacy of the antibody. This evidence concerns the gene CD4 and rheumatoid arthritis.